Cannabis use and obesity-traits: A Mendelian randomization study.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 34304124.
- Also identified by DOI 10.1016/j.drugalcdep.2021.108863.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Observational studies suggested that cannabis use is associated with decreased body fatness; however, observational studies are subject to confounding, making causal inference and determining the direction of these associations difficult. We performed Mendelian randomization (MR) using summary statistics from genome-wide association studies (GWAS) to investigate the potential causal association of cannabis use and obesity-related traits. We used 51 single nucleotide polymorphisms (SNPs) associated with lifetime cannabis use at P 1<× 10<sup>-5</sup> from a GWAS of 184,765 individuals of European descent and 27 SNPs genome-wide associated with cannabis use disorder as instrumental variables. The GWAS for body mass index (BMI) was derived from a meta-analysis of up to 322,154 individuals, and the GWAS for waist circumference (WC) and waist-hip ratio (WHR) included 210,088 participants. MR showed that lifetime cannabis use (beta = - 0.018, 95 % confidence interval (CI): - 0.05-0.015; P-value = 0.279, Q-value = 0.279) and cannabis use disorder (beta = 0.023, 95 % CI: 0.023-0.045; P-value = 0.034, Q-value = 0.092) were not associated with BMI. Considering WC and WHR as indicators of obesity, our findings did not support a causal association. Leave-one out analyses and pleiotropy-robust methods did not indicate bias in any of the estimates. Overall, the MR study provides little evidence that cannabis influences obesity related traits.
Medical subject headings
- Cannabis